MVA of survival outcomes in patients with inv(16)
| Covariate . | HR . | 95% CI . | P . |
|---|---|---|---|
| inv(16) DFS | |||
| Hypodiploidy vs pseudodiploidy | 0.532 | 0.122-2.325 | .402 |
| Hyperdiploidy vs pseudodiploidy | 0.681 | 0.339-1.370 | .281 |
| Trisomy 8 | 0.686 | 0.335-1.406 | .303 |
| Presence of secondary chromosomal abnormalities | 0.916 | 0.520-1.613 | .762 |
| inv(16) OS | |||
| Trisomy 8 | 0.397 | 0.184-.854 | .018 |
| Other chromosomal abnormalities | 2.052 | 1.186-3.550 | .010 |
| Covariate . | HR . | 95% CI . | P . |
|---|---|---|---|
| inv(16) DFS | |||
| Hypodiploidy vs pseudodiploidy | 0.532 | 0.122-2.325 | .402 |
| Hyperdiploidy vs pseudodiploidy | 0.681 | 0.339-1.370 | .281 |
| Trisomy 8 | 0.686 | 0.335-1.406 | .303 |
| Presence of secondary chromosomal abnormalities | 0.916 | 0.520-1.613 | .762 |
| inv(16) OS | |||
| Trisomy 8 | 0.397 | 0.184-.854 | .018 |
| Other chromosomal abnormalities | 2.052 | 1.186-3.550 | .010 |
All MVAs were adjusted for age, WBC count at diagnosis, and KIT mutation (positive, negative, and not tested).